(Q54622155)

English

A phase II trial of bryostatin-1 in patients with metastatic or recurrent squamous cell carcinoma of the head and neck.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/12003188

A phase II trial of bryostatin-1 in patients with metastatic or recurrent squamous cell carcinoma of the head and neck. (English)

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/12003188

phase II clinical trial

0 references

8

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/12003188

Michael J Zelefsky

13

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/12003188

Suzanne L Wolden

12

object named as

Suzanne Wolden

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/12003188

9

object named as

Dennis Kraus

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/12003188

Bhuvanesh Singh

11

object named as

Bhuvanesh Singh

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/12003188

10

object named as

Ashok Shaha

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/12003188

Andrew J Zahalsky

3

object named as

Andrew J Zahalsky

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/12003188

5

object named as

Eric Lis

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/12003188

author name string

David G Pfister

1

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/12003188

John McCaffrey

2

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/12003188

Gary K Schwartz

4

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/12003188

William Gerald

6

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/12003188

Andrew Huvos

7

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/12003188

Ilana Palgi

14

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/12003188

publication date

1 February 2002

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/12003188

Investigational New Drugs

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/12003188

20

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/12003188

1

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/12003188

123-127

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/12003188

https://scigraph.springernature.com/pub.10.1023/a:1014449309165

0 references

The in vivo effect of bryostatin-1 on paclitaxel-induced tumor growth, mitotic entry, and blood flow

1 reference

https://pubmed.ncbi.nlm.nih.gov/12003188

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee

1 reference

https://pubmed.ncbi.nlm.nih.gov/12003188

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Modulation of protein kinase C in antitumor treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/12003188

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II study of bryostatin 1 in metastatic malignant melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/12003188

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Optimal two-stage designs for phase II clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/12003188

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12003188

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I study of intravenous bryostatin 1 in patients with advanced cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/12003188

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacology and clinical experience with bryostatin 1: a novel anticancer drug

1 reference

https://pubmed.ncbi.nlm.nih.gov/12003188

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reporting results of cancer treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/12003188

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1023/A:1014449309165

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/12003188

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/12003188

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54622155&oldid=1739962698"